Logo do repositório
 
Publicação

Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review

2025-09Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorDamásio, Inês L
dc.contributor.authorFigueiredo, Ana
dc.contributor.authorMaciel, Joana
dc.contributor.authorHorta, Mariana
dc.contributor.authorSilva, Tiago N
dc.contributor.authorSimões-Pereira, Joana
dc.contributor.authorDonato, Sara
dc.contributor.authorLeite, Valeriano
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblEdizioni Minerva Medica S.p.A.
dc.date.accessioned2024-06-20T00:38:28Z
dc.date.available2024-06-20T00:38:28Z
dc.date.issued2025-09
dc.description.abstractBACKGROUND: Treatment of advanced differentiated thyroid carcinoma (DTC) remains a challenge as 25-50% of patients with locally invasive or distant metastatic disease become refractory to radioiodine (RAI) therapy. Tyrosine kinase inhibitors (TKI) are increasingly used in this setting. The SELECT trial demonstrated that lenvatinib, a multikinase inhibitor, significantly improved progression free survival (PFS) compared to placebo. Our aim was to report the effectiveness and safety of lenvatinib in our series of patients with advanced DTC. METHODS: A total of 25 patients with advanced DTC followed at a single tertiary center from January of 2016 to January of 2022 were retrospectively reviewed. RESULTS: Patients were treated with a mean daily dose of lenvatinib of 16.9 mg for a mean of 9.1 months. Median estimated PFS was 31.3 months. One patient achieved complete response. The objective response rate (ORR) was 40% and the disease control rate was 84%. The mean change in summed longest diameter of target lesions from baseline to nadir was -36.9%. Lenvatinib prolonged the tumor volume doubling time in 86.7% patients. Interestingly, we found that patients treated with a lower dose of lenvatinib (<16.9 mg daily) had a significantly higher PFS and ORR than patients treated with higher dosages (>16.9 mg). Adverse events were frequently reported. CONCLUSIONS: Our results confirm the effectiveness of lenvatinib in the management of patients with advanced DTC and support the need to adjust the dosage of lenvatinib to patient´s performance status and comorbidities.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent959158
dc.identifier.doi10.23736/S2724-6507.23.03982-9
dc.identifier.issn2724-6116
dc.identifier.otherPURE: 93042996
dc.identifier.otherPURE UUID: 7608ff8e-8b77-40b3-af08-47a03b3eb0b9
dc.identifier.otherPubMed: 38512702
dc.identifier.otherScopus: 105017895083
dc.identifier.urihttp://hdl.handle.net/10362/168817
dc.language.isoeng
dc.peerreviewedyes
dc.subjectThyroid neoplasms
dc.subjectLenvatinib
dc.subjectTyrosine kinase inhibitor
dc.subjectSDG 3 - Good Health and Well-being
dc.titleEffectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature reviewen
dc.typejournal article
degois.publication.firstPage276
degois.publication.issue3
degois.publication.lastPage285
degois.publication.titleMinerva endocrinology
degois.publication.volume50
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
R07Y9999N00A24032101.pdf
Tamanho:
936.68 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica